

Response ID ANON-E6MX-3EKG-A

Submitted to **Allowing schools to hold spare adrenaline auto-injectors**
Submitted on **2017-05-05 16:16:52**

Introduction

Tell us about yourself

1 What is your name?

Title(Mr, Mrs, Ms, Dr, Professor):

Mrs

First name:

Katie

Surname:

Perkins

2 What is your email address?

Email:

consultations@rpharms.com

3 Are you responding as an individual or as part of an organisation?

Organisation

Individual or organisation:

Royal Pharmaceutical Society

What is the role of your organisation:

The professional body for pharmacists and pharmacy in Great Britain

England

where are you or your organisation based.:

We represent Great Britain

4 If you are responding as an individual, please tell us your ethnic origin:

Not Answered

If other, please describe your ethnic origin:

Not Answered

If other, please give details of your ethnic background.:

Not Answered

If other, please enter details of your ethnic background:

Not Answered

If other, please give details of your ethnic origin.:

Not Answered

If other, please provide details of your ethnic background:

Not Answered

Consultation questions

5 Your response to the proposals

I support the proposals.

Please let us know if you have any comments on the proposals :

We believe that allowing schools to hold spare adrenaline auto-injectors will provide clear benefits for patients in terms of access and safety.

Please let us know if you have any comments on the issues intended to be addressed in the draft guidance :

We support the issues that intend to be addressed in the draft guidance. In addition, the guidance should be clear that those administering AAls require appropriate training and that they should be made aware of practical elements such as checking of expiry dates before administration as well as recording the expiry dates of stock that is held, ensuring this is replaced when necessary.

The training and guidance needs to include clear information on the different strengths of AAI that are available for children of different body-weights, ages and for those at risk of severe anaphylaxis. It also needs to be clear that different devices may have different instructions for administration.

We suggest that guidance should be included on the safe and appropriate disposal of discharged AAls into appropriate sharps containers and the collection of these. There should also be guidance on how unused expired stock should be disposed of.

The guidance should include clear information that an ambulance must always be called when there is a case of suspected anaphylaxis, including when adrenaline has been administered.

The guidance needs to include information on how schools should obtain stock of AAls, for example, they could be obtained via a signed order from a community pharmacy in the same way as schools obtain stock of salbutamol inhalers. It should also be made clear whether or not the community pharmacy would be required to hold a Wholesale Dealer's Licence (WDA(H)) to supply AAls to schools, or if the supply may be made under the MHRA statement (updated March 2014) 'Guidance for pharmacists on the repeal of Section 10(7) of the Medicines Act 1968'.

6 If you come into regular contact with a child/children at risk of anaphylaxis or work in a school or education environment please indicate in what capacity you have contact with children at risk of anaphylaxis.

If you ticked other please specify below:

7 Do you think this proposal would allow schools to access/receive AAls? What could be the implementation issues?

Comments:

8 If you are aware of a school that has pupils at risk of anaphylaxis can you confirm whether the school has existing protocols in place for the use of AAls? Are staff trained in the administration of AAls?

Comments:

9 If the school you are referring to became eligible for access to AAls, would it consider holding a spare device in its premises?

10 If you answered the above question with yes, can you please indicate how many AAls you are expecting to request/buy and use in a twelve month period under this proposal?

Comments:

11 If the school you are referring to held a spare AAI would additional training in its administration be necessary?

12 Can you identify any practical problems if schools are allowed to supply AAls for emergency use?

Comments:

13 Do you think this could encourage parents to not make sure that their children have AAls when they go to school?

14 Are you aware of any incidences of anaphylactic reaction where the pupil could not use their own AAls, in the past 12 months?

15 If you are a manufacturer of AAls: Considering the likely demand for AAls among the eligible groups under this proposal, how many additional AAls might you expect to sell per year?

Comments:

16 Are you happy for the Department of Health to use your email address to contact you to clarify points in your response if necessary?

Yes

17 How we will use your response

Yes

Yes

Your response, Your organisation's name

18 Would you like to receive information about other DH consultations?

Yes

19 Help us improve how the department runs consultations by answering the following questions:

Very satisfied

Further comments::

Very satisfied

Further comments::